Purpose An important question in the sequencing of anticancer therapies in patients with glioblastoma (GBM) is whether concurrent anti-angiogenesis therapies improve or impair brain concentrations of concomitantly administered cytotoxic therapies. The purpose of this study is to assess the intratumoral disposition of temozolomide (TMZ) via microdialysis before and after bevacizumab in an intracranial GBM xenograft model.
Introduction
Glioblastoma (GBM) was considered a chemoresistant tumor until the alkylating therapy temozolomide (TMZ) was added to radiation therapy resulting in an improved median overall survival (OS) from 10 % with radiotherapy alone to 26 % with chemoradiation at 2 years in patients with newly diagnosed glioblastoma (GBM) [1] . The platform of TMZ in combination with radiotherapy has been further enhanced by the addition of some standard (i.e., carmustine wafers) and several experimental anti-cancer drugs, achieving up to 37 % OS at 2 years in some patients [2, 3] . Despite these gains, the enthusiasm for the development of effective drug therapies for GBM has been tempered by the repeated failure to achieve durable clinical responses.
One factor contributing to the poor clinical performance of many drugs against brain cancer is limited access to tumor across the blood brain barrier (BBB) [4, 5] . The BBB is a physical and physiologic barrier that restricts entry of exogenous compounds, including many anti-cancer therapies, to the brain [4, 6] . TMZ is a small (MW 194.15) alkylating drug known to cross the BBB with an average AUC extracellular fluid (ECF)/plasma of 18 ± 4 % in patients [7] and 19.3 ± 9.6 % in rat glioma models [8] . TMZ given in standard dosing achieves better intratumoral concentrations than many cytotoxic therapies [4, 7] ; however, there is preclinical evidence that there is incremental improvement in TMZ's efficacy against glioma cells with higher intratumoral concentrations [9, 10] . These data suggest that interventions that either increase or decrease intratumoral TMZ concentrations may correspondingly improve or impair the efficacy of TMZ against GBM.
Tumor-driven angiogenesis results in irregular and leaky endothelium in GBM [11] . This process contributes to the abnormal BBB common in GBM and is driven largely by vascular endothelial growth factor (VEGF) signaling [12] . Intensive investigation of anti-angiogenesis agents in GBM is ongoing, and several such agents have been shown to normalize the BBB in preclinical models and in patients [11, 13] . Treatment with bevacizumab (BEV), a monoclonal antibody against VEGF, has resulted in durable objective radiographic response rates and improved clinical function in some patients with recurrent GBM, leading to accelerated approval by the Food and Drug Administration (FDA) for this indication [14, 15] . BEV is currently under investigation for patients with newly diagnosed GBM in combination with standard TMZ and radiotherapy (NCT00884741; NCT00943826). Combining anti-angiogenesis agents with cytotoxic therapies such as TMZ may be an effective strategy for patients with GBM [14] [15] [16] . However, to date there has been no demonstrated improvement in OS with this approach, and it is unknown whether normalization of the BBB via anti-angiogenesis agents enhances [17] [18] [19] or restricts [18, 20, 21] delivery of concurrent chemotherapies to glioma cells. Restriction of TMZ to glioma cells may be an unintended adverse effect of BEV combination therapy that could negatively impact overall therapeutic efficacy. To assess the impact of BEV on intratumoral TMZ concentrations, we used microdialysis to measure the brain extracellular fluid (ECF) concentration of TMZ before and after BEV in vivo in an intracranial U87 glioma model. Such data are critical for enhancing our understanding of potential therapeutic interactions that may influence clinical dosing schedules.
Materials and methods

Materials
TMZ (Schering Corporation, a subsidiary of Merck & Co., Inc. NJ, USA) and BEV (lot # 705413, Genentech, Inc. CA, USA) were purchased from the Johns Hopkins pharmacy. CMA12 microdialysis brain probes (membrane length 2 mm, shaft diameter 0.6 mm, shaft length 14 mm, membrane diameter 0.5 mm, polyarylethersulfone membrane), CMA 120 bowl system for freely moving animals, CMA 402 Syringe Pump, microsyringes 10-mL glass with piston stroke 60 mm were commercially purchased from CMA (CMA Microdialysis Inc. MA, USA). The study was approved by the Johns Hopkins Animal Care and Use Committee, and all procedures were conducted with compliance with their regulations.
Cell culture
The U87 human glioma cell line (provided by Dr. John Laterra, Johns Hopkins University, Baltimore, MD) [22] was grown in MEM with Earle Salts and L-glutamine (MEM 1*Mediatech, Inc.) supplemented with 10 % fetal bovine serum (Gemini Bioproducts, Inc.), 2 mMol/L sodium pyruvate (Mediatech, Inc.), 0.1 mmol/L MEMnon-essential amino acids (Mediatech, Inc.), and penicillin-streptomycin (Mediatech, Inc.). The cells were grown at 37°C in a humidified incubator with 5 % CO 2 .
Implantation of tumor cells and microdialysis probes
Five male, athymic nude rats, 200-300 g each (Harlan Bioproducts, Madison, WI), were anesthetized with 0.6-0.8 mL of pharmaceutical grade ketamine and xyalzine, IP. The dosing for ketamine was 15 mg, and the dosing for xylazine was 1.5 mg. Anesthetized animals were secured in a stereotactic apparatus. The scalp was cleansed, and a midline incision was made to expose the skull. Two holes were drilled by an automatic drill in the skull 2 mm lateral (right and left) and posterior to the Bregma. Two guide cannulas with dummy catheters were placed to a depth of 4 mm. The guide cannula was secured to the skull with dental cement (Geristore Syringeable value kit A2, Denmat, Santa-Maria, CA,). A 25-lL Hamilton syringe with a 26-gauge needle attached to the stereotactic frame was used to inject 1 million U87 cells at a depth of 5 mm from the skull via guide cannula on the left striatum over 3-4 min. The needle was then withdrawn, and the skin was closed with sutures. After the surgery, the animals were given buprenorphine, 1 mg/kg SC, for analgesia. They were returned to their individual cages and received a regular rat diet and water ad libitum. The animals were monitored daily for weight loss or new neurological deficit.
Microdialysis methodology and ECF sample collection Based on prior serial MRI assessments of 4 rats with intracranial U87 tumors, we determined that the mean tumor diameter was 2.8 ± 0.93 mm at day 10 ( Fig. 1) . This is an optimal size as it ensures the probe is surrounded by tumor cells, but that the tumor size is not going to result in imminent herniation. Hence, on day 11 after tumor inoculation, the dummy catheters were replaced with 2 mm CMA12 microdialysis catheters, bilaterally (left = tumor side, right = normal brain). The inlet tubing was attached to a CMA microsyringe and pump, and lactated ringers solution was perfused through the catheter tip at a rate of 1 lL/min (Fig. 2) . After a 60 min period of equilibration, TMZ was administered to rats as a single oral dose at 50 mg/kg dissolved in water. Brain ECF dialysate collections were collected at baseline and every 60 min for 6 h. In vivo dialysate recovery experiments were performed at the end of the 6 h dialysate collection for bilateral probes. At the conclusion of the initial collection period, the microdialysis catheters were removed from the cannula and placed in lactated ringer solution. The dummy catheters were replaced. A single dose of bevacizumab (10 mg/kg) was injected via tail vein. The rats were returned to their cages with ad libitum diet, water, and activity and monitored for comfort.
Thirty-six hours after the BEV was dosed, rats were transiently re-anesthetized with ketamine and xyalzine, the microdialysis catheters were put in place of the dummy catheters, and the rats were replaced into the collection cages. The catheters were again perfused with a lactated ringer solution of 1 lL/min and allowed to equilibrate over 60 min. TMZ was again given as described above, now 36 h after BEV. Dialysate collection was continued every 60 min for 6 h. In vivo dialysate recovery experiments were done again at the conclusion of collection. All ECF samples were assessed for drug concentrations using liquid chromatography-tandem mass spectrometry (LC/MS/MS) over the concentration range of 0.02-5 lg/mL [8] . The inter-assay precision were all \15 %, and the accuracy expressed as the percentage error was within the range of ±15 % for microdialysate.
In vivo assessment of probe recovery
In vivo dialysate recovery experiments were done at the end of each collection period to allow estimation of in vivo recovery and assess the integrity of the microdialysis system. At the end of ECF collection, the probes were perfused at a rate of 1 lL/min with lactated ringer solution containing TMZ to determine the in vivo probe recovery using the retrodialysis method described elsewhere [8] .
Microdialysate samples were collected at 10-min intervals for 40 min, and the percentage relative recovery was calculated as follows [23, 24] :
where C perfusate is the drug concentration (2 lg/mL) in the perfusate and C dialysate is the drug concentration in the microdialysate, which was the average concentration for 2-4 samples at each collection time, for each probe. In the case of 1 animal where samples were not obtained, the average in vivo recovery for the other time points for that animal was used for further calculations. The recovery was utilized to estimate the estimated ECF concentration according to the equation: [23, 24] .
All animals were euthanized by perfusion, and their brains harvested, sectioned, and stained with H/E to demonstrate peri-probe tumor histology (Fig. 3) . In 2 animals, MRI of brain was also done with the probe in place to confirm position relative to the tumor (Fig. 1 ).
Pharmacokinetic analysis
Individual pharmacokinetic parameters for both raw and estimated ECF before and after administration of BEV were calculated by standard non-compartmental analysis using the WinNonlin version 5.3 (Pharsight Corporation, Mountain View, CA). The maximum plasma concentration (C max ) and the time of C max after oral administration (T max ) were obtained by visual inspection of the concentrationtime curve. The area under the plasma concentration-time curve (AUC) was calculated using the log-linear trapezoidal rule to the end of sample collection (AUC 0-5.5h ) and extrapolated to infinity (AUC 0-? ) by dividing the last quantifiable concentration by the terminal disposition rate constant (k z ), which was determined from the slope of the terminal phase of the concentration-time profile. The halflife (T 1/2 ) was determined by dividing 0.693 by k z . If the percent AUC extrapolated was greater than 50 %, then only the AUC 0-5.5h was reported.
Statistical analysis
The PK parameters were summarized using descriptive statistics. Differences in the PK parameters between 
Results
Pharmacokinetic of TMZ in brain ECF
Similar maximal and total exposure (C max and AUC 0-? ), T max , and T 1/2 values were found when TMZ was administered alone and with BEV (raw data: C max P = 0.32, AUC 0-? P = 0.75, T max P = 0.75, T 1/2 P = 1.00; corrected data: C max P = 0.38, AUC 0-? P = 1.00, T max P = 0.75, T 1/2 P = 1.00) ( Table 1 ; Fig. 4 ). The mean corrected TMZ ECF C max on the tumor side was 0.93 ± 0.77 lg/mL (mean ± SD), which occurred at a median time of 1.50 h. The area under the concentration curve (AUC 0-? ) was 3.35 ± 2.90 lg h/mL. After the administration of BEV, the mean corrected C max of ECF concentration of TMZ on the tumor side was 0.85 ± 0.85 lg/mL, which occurred at a median time of 1.50 h, and AUC 0-? was 3.98 ± 2.02 lg h/mL. This represented a 0.9-fold decrease in the C max and a 1.2-fold increase in TMZ mean AUC 0-? after BEV administration. The half-life was slightly decreased after BEV administration (1.84 ± 1.08 h pre vs. 1.30 ± 0.27 h post). On the contralateral side (non-tumor-bearing brain), before BEV administration, corrected C max of ECF of TMZ was 0.82 ± 0.68 lg/mL (mean ± SD), which occurred at a median time of 1.50 h, and AUC 0-? was 3.22 ± 2.62 lg h/mL. After the administration of BEV, the corrected C max of ECF concentration of TMZ was 1.06 ± 1.01 lg/mL, which occurred at a median time of 1.50 h, and the AUC 0-? was 3.34 ± 2.78 lg h/mL. This represented a 1.3-fold increase in the C max of ECF concentration of TMZ, and no change in mean AUC 0-? of ECF concentration of TMZ after BEV administration (Fig. 4) . The half-life was slightly prolonged after BEV administration (1.86 ± 0.50 h pre vs. 1.82 ± 0.83 h post). There was no statistical difference in parameters on the contralateral side (non-tumor bearing brain) (P [ 0.05).
Discussion
Cytotoxic and anti-angiogenic therapies will theoretically complement each other to decrease tumor cell proliferation, reduce tumor associated inflammation, and induce cancer cell death. Based on this principle, there are several ongoing clinical studies assessing the combination therapies of TMZ and BEV in patients with malignant gliomas. However, there is not yet any evidence that BEV improves OS in patients with GBM or that concurrent cytotoxic therapy with BEV has significant clinical benefit over BEV monotherapy [14, 15] . Moreover, it has been suggested that agents such as BEV may inadvertently decrease the intratumoral concentration of TMZ that has been proven to prolong OS when given with radiation therapy to patients with newly diagnosed GBM [17, 21] . We address the critical clinical question of the influence of BEV on TMZ intratumoral PK via direct sampling from intracranial U87 tumors with microdialysis catheters in the presence and absence of BEV.
Microdialysis is a technique that allows direct measurement of compounds in the ECF. The catheters are FDA approved for use in humans. They have been predominantly used in the setting of brain trauma and ischemia [25] . More recently, microdialysis catheters have been used to assess the delivery of cytotoxic chemotherapy to brain [4, 7, 8, 17-20, 26, 27] . This technique allows sampling of amenable drugs in the ECF surrounding tumor cells. Drug concentrations in the ECF compartment are thought to best represent bioavailable drug. Furthermore, the catheters can stay in place for several days allowing each animal to serve as its own control for both tumor and normal brain as well as for before and after treatment comparisons.
Although microdialysis is an informative technique, it has several limitations that have to be considered. Insertion of the microdialysis probe into tissue transiently disrupts the normal BBB. This is maximal immediately after insertion and is largely resolved 3-4 days after insertion [28] . We administered TMZ and performed the microdialysis studies on day 11 after insertion of the guide cannulas and tumor cells in order to both minimize the effect of the catheter placement on BBB disruption and ensure that the catheter membrane was centered in the tumor core. Another limitation of microdialysis is that the drug concentrations in dialysate are estimates of the true ECF concentrations [29] . To ensure as accurate as possible an estimation of ECF, we used a low flow rate (1 lL/min) and a drug shown to have excellent in vitro recovery [8] . In addition, we estimated the percent recovery via in vivo retrodialysis at the end of each study, for each catheter, to estimate TMZ recovery within the tissue environment [30] . Our retrodialysis recovery rates ranged between 58.5 ± 11.4 and 67.7 ± 10.7 % compared to rates of 87 ± 5.5 % seen in in vitro studies [7] . These rates suggest that the catheters were functional and with adequate recovery even at the end of an extended collection period.
The data from this study showed that there was no statistically significant difference in the intratumoral AUC of TMZ with or without BEV in U87 xenograft tissue versus normal brain (Fig. 4) . One possible explanation for this is that BEV, a humanized monoclonal antibody to VEGF, does not influence VEGF in a rat model. However, available data show that BEV does demonstrate therapeutic efficacy in orthotropic U87 models in athymic rats [31] [32] [33] as it was shown to cause a dose-dependent decrease in the relative cerebral blood volume (rCBV) as well as a decrease in the rate of tumor growth [31, 32] . BEV was also shown to influence brain tumor perfusion as assessed by ferumoxytol MRI in rats with U87 gliomas [31, 32, 34] . Hence, there is evidence for a biological effect of BEV in the U87 rat model.
Another possible explanation for the lack of observed difference between pre-and post-BEV TMZ concentrations is that U87 tumors are not angiogenic and therefore would not be expected to respond to BEV. However, the available literature shows that U87 tumors have an angiogenic phenotype [35, 36] . Specifically, U87 cells (in vitro) and tumors (in vivo) have been characterized as expressing vimentin and demonstrating angiogenic properties such as neovascularization in addition to malignant features such as hypercellularity, pleomorphism, nuclear atypia, and inflammation similar to human GBM [35] . Although U87 tumor do not generally show necrosis or invasion, they do demonstrate high vessel density, abnormally large and irregular blood vessels and a high density of cells staining for VEGF [36] . These properties make U87 a favorable model to assess the effects of anti-angiogenesis therapies on intratumoral PK. Finally, a well-recognized property of U87 tumors is rapid and predictable growth. This is an important quality for intracranial microdialysis studies allowing for optimal catheter placement within tumor core and sequential dosing of medications over time without animal morbidity due to large tumors.
A limitation of this study is that serial MRIs could not be done with the cannulas in place to demonstrate the variance in the degree of vascularization or the change in vascularization in response to BEV. In addition, rats were euthanized at the conclusion of the study, and tissue was harvested to confirm the spatial relationship of catheter to tumor (Fig. 3) , but additional testing of vascular markers was not available. An additional limitation of this study is that we do not have plasma levels to assess systemic TMZ exposure. However, TMZ plasma disposition has been well characterized in prior TMZ PK studies, and the comparison of tumor versus normal brain within animals across treatment conditions serves as an internal control. Overall, our TMZ PK values are similar to prior reports of brain TMZ concentrations both within human non-enhancing brain [7] and other preclinical glioma studies [17, 18, 37] (Table 2) .
One important consideration for the planned use of concomitant TMZ and BEV dosing is the intrinsic sensitivity of the tumor cells to TMZ and whether that may be influenced by concomitant BEV. U87 cells are sensitive to TMZ with an IC 50 of 472 ± 14 lM [38, 39] and show susceptibility to TMZ as measured by tumor response [40, 41] as well as prolonged survival [42] . There are also data to suggest that the positive anti-tumor effects of TMZ require adequate drug concentration [40] . Although assessment of tumor response to TMZ and BEV, alone or in combination, was beyond the scope of this PK study, the PK data presented here suggest that there is no interruption of TMZ access to tumor with BEV and therefore, no clear mechanism by which BEV would adversely influence the therapeutic effect of TMZ. In fact, it is possible that BEV could enhance the effect of TMZ on gliomas cells. Although there are no published data about the effect of BEV and TMZ in U87 models, in the Hs683 intracranial orthotropic glioma model, concurrent BEV and TMZ resulted in improved survival times versus either drug alone [38] .
It is expected that normal brain would not have a substantial change in TMZ with or without BEV, as was seen in this study. However, the lack of difference in TMZ PK between U87 tissue and normal brain was unexpected. It is possible that due to the relatively high penetration of TMZ across the BBB at baseline (Table 2) , the small sample size was not adequate to reflect the difference in TMZ concentrations between tumor and normal brain. In humans, disruption of the BBB as evidenced by contrast enhancement has been associated with higher levels of methotrexate than in non-contrast enhancing regions of brain [27] . The only human data about TMZ disposition in brain are from regions of relative BBB integrity [7] . In preclinical models, combining TMZ and angiogenesis inhibitors has led to inconsistent TMZ concentration results dependent on the tumor model, tumor location, anti-angiogenesis agent, and vehicle used (Table 2 ) [8, 17, 18, 20, 37] . In a U87 orthotropic model, Zhou and Gallo showed that TMZ concentrations were higher in tumor versus normal brain [19] . However, this study assessed drug concentrations in tumor homogenate at steady state and hence is not directly comparable to the ECF concentrations reported here. Devineni et al. showed reduction in TMZ in a subcutaneous (SC) C6 tumor model with TNP-470 (a synthetic analog of fumagillin shown to inhibit angiogenesis) [20] . Ma et al. found similar results in both SC and intracranial models using the human-derived cells engineered to express high levels of VEGF (SF188V?) treated with TNP-470 [17] . However, in that same tumor model, the pan-kinase inhibitor sunitinib resulted in decreased TMZ concentrations in the peripheral tumors but increased TMZ concentrations in intracranial tumors [18] . Further investigation of the effect of sunitinib on intratumoral concentration of TMZ was undertaken in an intracranial U87 model and again showed a dose-dependent effect of sunitinib such that low dose enhanced TMZ concentrations intracranially, but high dose reduced TMZ concentrations [19] . The cumulative view of this data is that the impact of anti-angiogenesis agents on cytotoxic drug concentrations in the brain is dependent on the agents in question as well as the tumor response to anti-angiogenesis therapy. In this study, we chose to evaluate BEV as it is the only anti-angiogenesis agent with FDA approval for use in recurrent GBM. TMZ is currently used to treat patients with newly diagnosed and recurrent GBM. Of note, TMZ showed mixed activity as a single agent in patients with both recurrent and newly diagnosed GBM in early clinical investigation and was initially approved for use in patients with recurrent anaplastic astrocytoma [43, 44] . TMZ given concurrently with radiation therapy has shown significantly improved OS in patients with GBM [1] . It is possible that TMZ and radiation therapy are synergistic. An alternative hypothesis is that there is improved access of TMZ to tumor across a BBB disrupted by radiation therapy [45] .
There are currently two large phase III trials investigating the combination of BEV, TMZ, and radiation therapy in patients with newly diagnosed GBM (NCT00884741; NCT00943826). The results from the present study show that there are no statistically significant changes in TMZ concentrations before and after BEV in a U87 glioma xenograft model. These results are encouraging and suggest that with a dosing scheme similar to what is being used clinically, TMZ is not restricted from brain tissue with concomitant BEV. Additional studies with agents that have lower brain penetration than TMZ will provide additional data about the role of BEV in enhancing or restricting access of drugs that have low baseline penetration across the BBB. Preclinical assessment of intracranial PK in experimental models may prove a significant clinical predictor of effective clinical dosing strategies assisting in the rationale development of clinical paradigms with combination therapies.
